FIELD: pharmaceuticals.
SUBSTANCE: invention refers to compounds presented by formulas (I)–(XVIII), or their pharmaceutically acceptable salts and pharmaceutical compositions based thereon.
EFFECT: there are prepared new compounds possessing PAR2 inhibitory activity suitable for treating inflammatory skin disease or inflammatory intestinal disease.
15 cl, 8 tbl, 24 ex
Title | Year | Author | Number |
---|---|---|---|
HETEROCYCLIC COMPOUND | 2018 |
|
RU2791533C2 |
DIAMINE DERIVATIVES | 2003 |
|
RU2333203C2 |
DERIVATIVES OF CYCLOHEXANE OR TETRAHYDROPYRANE OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, OR HYDRATES, OR SOLVATES OF THESE COMPOUNDS, OR THEIR SALTS, INTERMEDIATE COMPOUNDS FOR THEIR SYNTHESIS AND FUNGICIDE AGENT | 1992 |
|
RU2084439C1 |
CYCLOALKANE-1,3-DIAMINE DERIVATIVE | 2019 |
|
RU2793247C2 |
COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | 2013 |
|
RU2661896C2 |
ANTIBACTERIAL AGENT | 2000 |
|
RU2269525C2 |
AMINOPYRIMIDINE DERIVATIVES AND USE THEREOF AS AROMATIC HYDROCARBON RECEPTOR MODULATORS | 2021 |
|
RU2826628C1 |
N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2669922C2 |
PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION SHOWING ABILITY TO INHIBIT GABA RECEPTORS, AND DRUG FOR TREATING AND PREVENTING DISORDERS ASSOCIATED WITH GABA RECEPTOR INHIBITION | 2007 |
|
RU2458063C2 |
Authors
Dates
2020-12-30—Published
2017-08-29—Filed